The Way To Recognise A Real ABT-263

R; median EFS, 3.5 vs 7.7 months, p=0.600; median OS, 7.6 vs 11.5 months, p=0.129, http://www.selleckchem.com/products/MK-2206.html respectively). Response rates following ASCT were 60% and 68% in C and R groups, respectively (p=0.165). Univariate and multivariate analyses revealed age-adjusted IPI score at the time of ASCT (2 or 3) and relapse or progression less than 12 months after diagnosis were the independent prognostic factors for both EFS (Hazard ratio [HR] for multivariate analysis; 7.16 [p http://www.selleck.cn/products/Erlotinib-Hydrochloride.html Age-adjusted IPI and time to relapse or progression after diagnosis, but not previous rituximab exposure were associated with clinical outcomes of patients with relapsed or refractory DLBCL treated with HDT/ASCT. 384 SIMPLE PROGNOSTIC PARAMETERS IN DLBCL: PRETREATMENT SERUM ALBUMIN LEVEL AS AN INDEPENDENT PREDICTOR FOR EFS AND OS R. Gurion, A. Shacham-Abulafia, O. Spilberg, O. Bairey. Hematology Institute, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel Introduction: The International Prognostic Index (IPI) is a widely used and accepted prognostic model for diffuse large B cell lymphoma (DLBCL). In the last years, several groups looked for additional simple prognostic parameters, not included in the original IPI, i.e. absolute lymphocyte count (ALC), absolute monocyte count (AMC) and absolute neutrophil count (ANC), with diverse Results: The aim of the present study is to evaluate the prognostic value of these parameters such as, ALC, AMC, ALC/AMC, ANC/ALC, hemoglobin and albumin level at diagnosis in patients with DLBCL and compare with known prognostic models as IPI and R-IPI. Methods: We retrospectively reviewed data of 166 adult patients with DLBCL who were diagnosed at Rabin Medical Center, Israel, between the years 2004- 2008. The mean age was 63.4 years, 43% were male, 62% with stage III/IV, 28% with ECOG performance status 0-2, 59% with elevated LDH level and 85% were initially treated with R-CHOP. The median follow up was 6.6 years (range 3.6-9 year). Results: The 5 years overall survival (OS) for the entire group was 67.5%; for patients with lower IPI (0-2) http://www.selleckchem.com/products/ABT-263.html �C 76% (n=83); and for patients with higher IPI (3-5) �C 48.8% (n=80). In univariate analysis, pretreatment hemoglobin and albumin levels had statistically significant effect on event free survival (EFS) and OS. Five years OS was 77.3% in patients with pretreatment albumin >3.5 g/dl, compared with 47.9% in patients with albumin level 12g/dl, compared with 56.5% in patients with hemoglobin level